Predictive Oncology To Be Acquired by Renovaro: A Milestone in AI-Driven Drug Discovery

Predictive Oncology Inc., a leader in AI-driven drug discovery, announced its agreement to be acquired by Renovaro, Inc. in a deal that aligns shareholder interests and heralds a new era of scientific synergies. The merger intends to utilize complementary artificial intelligence and machine learning platforms to enhance patient outcomes across various cancer treatments. The agreed terms include the exchange of Predictive Oncology common stock for preferred stock in Renovaro, which can be redeemed or converted under specific circumstances. The merger promises to deliver significant operational cost savings, improve early cancer diagnosis, and accelerate targeted therapy development. It is contingent on Renovaro's fundraising and shareholder approval, with plans to finalize definitive documentation by February 2025. The collaboration represents a strategic alignment with potential long-term impacts on cancer treatment efficacy and personalization.